ASP Isotopes (ASPI) Projected to Post Earnings on Friday

Key Points

• Q1 2026 earnings preview: ASP Isotopes is set to report results after the close on Friday, May 15, with analysts forecasting a loss of ($0.28) per share and revenue of $3.676 million; the earnings call is scheduled for Thursday, May 14 at 4:00 PM ET.
• Prior quarter contrast: On April 10 the company posted a large EPS miss of ($0.84) versus a ($0.14) estimate, yet reported revenue of $33.32 million (well above estimates), and displayed a negative net margin (734.14%) and ROE (-161.55%).
• Insider selling: Director Duncan Moore and COO Robert Ainscow sold shares on April 16 (11,642 and 22,500 shares); insiders have sold 90,704 shares (~$463,252) in the past 90 days and currently own 14.40% of the stock.

ASP Isotopes (NASDAQ:ASPI - Get Free Report) is anticipated to announce its Q1 2026 results after the market closes on Friday, May 15th. Analysts expect the company to announce earnings of ($0.28) per share and revenue of $3.6760 million for the quarter. Investors can check the company's upcoming Q1 2026 earning summary page for the latest details on the call scheduled for Thursday, May 14, 2026 at 4:00 PM ET.

ASP Isotopes (NASDAQ:ASPI - Get Free Report) last posted its earnings results on Friday, April 10th. The company reported ($0.84) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.14) by ($0.70). ASP Isotopes had a negative net margin of 734.14% and a negative return on equity of 161.55%. The firm had revenue of $33.32 million during the quarter, compared to analyst estimates of $2.03 million.

ASP Isotopes Price Performance

Shares of ASP Isotopes stock opened at $5.33 on Friday. The firm has a market cap of $671.05 million, a PE ratio of -2.49 and a beta of 3.26. ASP Isotopes has a twelve month low of $3.92 and a twelve month high of $14.49. The company has a quick ratio of 12.20, a current ratio of 12.23 and a debt-to-equity ratio of 0.77. The business has a 50-day moving average price of $5.04 and a 200 day moving average price of $6.26.

Analysts Set New Price Targets

Several analysts have commented on ASPI shares. Weiss Ratings reissued a "sell (d-)" rating on shares of ASP Isotopes in a report on Friday, March 27th. Canaccord Genuity Group reiterated a "buy" rating and set a $11.00 target price on shares of ASP Isotopes in a research report on Tuesday, April 14th. Two investment analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company. According to MarketBeat.com, ASP Isotopes currently has an average rating of "Hold" and an average target price of $13.00.

Insider Activity at ASP Isotopes

In other ASP Isotopes news, Director Duncan Moore sold 11,642 shares of the business's stock in a transaction on Thursday, April 16th. The stock was sold at an average price of $5.21, for a total transaction of $60,654.82. Following the transaction, the director owned 1,044,928 shares of the company's stock, valued at approximately $5,444,074.88. The trade was a 1.10% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website. Also, COO Robert Ainscow sold 22,500 shares of the company's stock in a transaction on Thursday, April 16th. The shares were sold at an average price of $5.21, for a total value of $117,225.00. Following the completion of the sale, the chief operating officer owned 1,490,317 shares of the company's stock, valued at approximately $7,764,551.57. The trade was a 1.49% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Over the last 90 days, insiders sold 90,704 shares of company stock valued at $463,252. 14.40% of the stock is currently owned by insiders.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently modified their holdings of the company. Quantbot Technologies LP acquired a new position in ASP Isotopes in the third quarter valued at about $34,000. BNP Paribas Financial Markets increased its position in shares of ASP Isotopes by 84.9% during the second quarter. BNP Paribas Financial Markets now owns 5,549 shares of the company's stock valued at $41,000 after acquiring an additional 2,548 shares during the last quarter. Guggenheim Capital LLC acquired a new stake in shares of ASP Isotopes during the fourth quarter valued at about $72,000. Caption Management LLC raised its stake in shares of ASP Isotopes by 110.5% in the 4th quarter. Caption Management LLC now owns 13,800 shares of the company's stock valued at $74,000 after acquiring an additional 145,800 shares during the period. Finally, Steward Partners Investment Advisory LLC acquired a new position in shares of ASP Isotopes in the 4th quarter worth approximately $74,000. Institutional investors and hedge funds own 16.80% of the company's stock.

ASP Isotopes Company Profile

ASP Isotopes Inc, a development stage advanced materials company, focuses on the production, distribution, marketing, and sale of isotopes. It engages in the production and commercialization of Molybdenum-100, a non-radioactive isotope for the medical industry; Carbon-14; and Silicon-28. The company is also developing Quantum Enrichment technology to produce Ytterbium-176, Nickel-64, Lithium 6, Lithium7, and Uranium-235. ASP Isotopes Inc was incorporated in 2021 and is headquartered in Washington, District Of Columbia.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.